TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| Biovest Meets Skeptic’s Requirements for 'The Next Dendreon' (Part 1) James Hill, MD submits: Minyanville’s biotech analyst David Miller may not recognize it, but Biovest International (BVTI.PK) appears to meet his qualifications for the next big success story in cancer vaccines. Following the FDA’s April 2010 landmark approval of Dendreon’s (DNDN) Provenge as the first active vaccine for cancer, enthusiasm runs high for other immunotherapy companies to find similar success. But Miller appropriately urges caution.Complete Story » seekingalpha.com |
St. Jude Earnings Climb On Heart-Rhythm Devices St. Jude Medical posted a 16% climb in second-quarter earnings and raised its full-year forecast, backed by sales gains in a heart-rhythm devices business. online.wsj.com |
Girls Reaching Puberty Earlier New research adds further evidence that girls are entering puberty at younger and younger ages, with implications for their physical and mental health. online.wsj.com |
Amyris Completes IPO With Impressive Partnerships Pipeline: Biotech's Latest Deals The Burrill Report submits: By Marie Daghlian Amyris (AMRS) has completed its much anticipated initial public offering, raising $84.8 million. Though the deal priced at $16 per share, below its expected $18 to $20 range, it posted a 5 percent gain in its first day of trading. Complete Story » seekingalpha.com |
Obesity Drug Not Approved by FDA The U.S. Food and Drug Administration declined to approve Arena Pharmaceuticals's obesity drug lorcaserin, raising questions about the drug's effectiveness and seeking more information about its cancer risk. online.wsj.com |